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Tetraspanins are a family of proteins with four transmembrane domains that associate 
between themselves and cluster with other partner proteins, conforming a distinct class 
of membrane domains, the tetraspanin-enriched microdomains (TEMs). These TEMs 
constitute macromolecular signaling platforms that regulate key processes in several 
cellular settings controlling signaling thresholds and avidity of receptors. In this study, 
we investigated the role of CD9, a tetraspanin that regulates major biological processes 
such as cell migration and immunological responses, in two mouse models of colitis that 
have been used to study the pathogenesis of inflammatory bowel disease (IBD). Previous 
in vitro studies revealed an important role in the interaction of leukocytes with inflamed 
endothelium, but in vivo evidence of the involvement of CD9 in inflammatory diseases is 
scarce. Here, we studied the role of CD9 in the pathogenesis of colitis in vivo. Colitis was 
induced by administration of dextran sodium sulfate (DSS), a chemical colitogen that 
causes epithelial disruption and intestinal inflammation. CD9−/− mice showed less severe 
colitis than wild-type counterparts upon exposure to DSS (2% solution) and enhanced 
survival in response to a lethal DSS dose (4%). Decreased neutrophil and macrophage 
cell infiltration was observed in colonic tissue from CD9−/− animals, in accordance with 
their lower serum levels of TNF-α, IL-6, and other proinflammatory cytokines in the colon. 
The specific role of CD9 in IBD was further dissected by transfer of CD4+ CD45RBhi 
naive T cells into the Rag1−/− mouse colitis model. However, no significant differences 
were observed in these settings between both groups, ruling out a role for CD9 in IBD 
in the lymphoid compartment. Experiments with bone marrow chimeras revealed that 
CD9 in the non-hematopoietic compartment is involved in colon injury and limits the 
proliferation of epithelial cells. Our data indicate that CD9 in non-hematopoietic cells 
plays an important role in colitis by limiting epithelial cell proliferation. Future strategies to 
repress CD9 expression may be of therapeutic benefit in the treatment of IBD.
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inTrODUcTiOn
Inflammatory bowel disease (IBD) defines a group of intestinal disorders, principally, ulcerative 
colitis (UC) and Crohn’s disease (CD). Both diseases are characterized by chronic inflammation of 
the gastrointestinal tract interspersed with relapsing phases (1). Much progress has been made in 
understanding UC and CD disease mechanisms, for example, through genome-wide association 
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studies in patients; however, these diseases remain incompletely 
understood. Identified genetic risk loci have revealed defects in 
IBD patients affecting genes crucial for intestinal homeostasis, 
including epithelial barrier function, restitution, and wounding 
(2). Moreover, recent clinical studies have revealed mucosal 
healing (MH) as the major prognostic predictor of long-term 
remission in IBD patients (3, 4), suggesting that epithelial regen-
eration is critical to improving IBD therapy (5).
Tetraspanins are proteins that span the cell membrane 
four times and play an important role in plasma membrane 
organization through the formation of tetraspanin-enriched 
microdomains, which enable them to associate with multiple 
proteins, including other tetraspanins (6). The tetraspanin CD9 
is broadly expressed on the surface of several cell types, including 
many malignant tumor cells, as well as normal hematopoietic, 
endothelial, and epithelial cells (7, 8). Soon after its identification, 
CD9 was found to associate with several integrins (9), enabling 
CD9 to exert pro- or anti-migratory effects (10). CD9 can also 
interact with the immunoglobulin superfamily members EWI-2 
and EWI-F (11), DDR1 (12), other tetraspanins (e.g., CD81 and 
CD151) (13), claudin-1 (14), ADAM10 (15), and ADAM17 (16) 
metalloproteases, epidermal growth factor receptor (EGFR) (17), 
and membrane-bound EGFR ligands (18, 19). Moreover, CD9 
has been reported to regulate endothelial nanoscopic organiza-
tion and expression levels of ICAM-1 and VCAM-1 upon TNF-α 
activation, enabling formation of the docking structure required 
for leukocyte extravasation (20, 21). Anti-CD9 agonistic antibod-
ies or ectopic expression of CD9 both exert an antiproliferative 
effect on human colon carcinoma cell lines (22). However, the 
role of CD9 in IBD has not been previously addressed in vivo. 
Here, we show that CD9 acts as a limiting factor for epithelial 
regeneration and colonic MH in dextran sodium sulfate (DSS)-
induced colitis.
MaTerials anD MeThODs
Mice
Experiments were performed with sex and age matched (8- to 
12-week old) CD9−/− and WT mice on the C57BL/6 background. 
CD9−/− mice have been described previously (23). Rag1−/− mice 
(24) used in the adoptive transfer colitis model were kindly 
provided by Dr. J. M. Fernández-Granado (CNIC). For chimeric 
reconstitution experiments, B6SJL CD45.1 mice (Jackson 
Laboratories) were used. All animals were housed in pathogen-
free conditions at the CNIC animal facility. Experimental proce-
dures were approved by the local research ethics committee and 
conformed to EU Directive 2010/63EU and Recommendation 
2007/526/EC, enforced in Spanish law under Real Decreto 
53/2013.
induction and assessment  
of Dss-induced colitis
Dextran sulfate sodium salt (DSS, MP Biomedicals; MW = 36,000–
50,000) was dissolved at 2 or 4% (w/v) in sterile drinking water 
provided to mice ad libitum. Mice were checked daily for devel-
opment of colitis by monitoring body weight, fecal occult blood 
(Hemoccult II Sensa; Beckman Coulter) or gross rectal bleeding, 
and stool consistency. Overall disease severity was assessed by a 
clinical scoring system defined as follows: weight loss: 0 (no loss), 
1 (1–5%), 2 (5–10%), 3 (10–20%), and 4 (>20%); stool consist-
ency: 0 (normal), 2 (loose stool), and 4 (diarrhea); and bleeding: 
0 (no blood), 1 (Hemoccult positive), 2 (Hemoccult positive 
and visual pellet bleeding), and 4 (gross bleeding, blood around 
anus). At the end of the experiment, tissues were fixed in 10% 
neutral buffered formalin (Bio Optica) for 24 h and transferred 
to 70% ethanol. After embedding in paraffin, transverse sections 
(4–5 µm) of proximal and distal colon were stained with H&E 
for histological studies. Images were digitized using Hamamatsu 
Nanozoomer 2.0 RS scan and NDP.scan 2.5 digitization software. 
Three images of two serial sections cut at a separation of 100 µm 
(six sections in total) were evaluated for each mouse for each 
part of the colon (proximal and distal). Histological scoring 
evaluated inflammation severity, crypt damage, and ulceration. 
Inflammation severity was scored as follows: 0, rare inflammatory 
cells in the lamina propria; 1, increased numbers of granulocytes 
in the lamina propria; 2, confluence of inflammatory cells extend-
ing into the submucosa; 3, transmural extension of the inflam-
matory infiltrate. Crypt damage was scored as follows: 0, intact 
crypts; 1, loss of the basal one-third; 2, loss of the basal two-thirds; 
3, entire crypt loss; 4, change of epithelial surface with erosion; 5, 
confluent erosion. Ulceration was scored as follows: 0, absence of 
ulcers; 1, 1–2 ulceration foci; 2, 3–4 ulceration foci; 3, confluent 
or extensive ulceration. Scores for each parameter were summed 
to give a maximum histological score of 11.
T cell-Mediated colitis
Naive CD4+ T  cells were sorted (FACSaria sorter, BD) from 
single-cell spleen suspensions of CD9−/− or WT mice. Live 
cells were isolated after labeling with antibodies to CD4, CD62, 
CD25, and CD45RB (eBiosciences) and hoescht 33258. Cells 
were transferred to recipient mice (4–5 × 105 cells per mouse) by 
intraperitoneal injection.
Bone Marrow chimeras
Bone marrow transfer was used to create chimeric mice in which 
genetic deficiency for CD9 was confined to either circulating cells 
(CD9−/− >  WT) or nonhematopoietic tissue (WT >  CD9−/−). 
Briefly, bone marrows were collected from femur and tibia of 
congenic WT donor mice (expressing CD45.1 leukocyte antigen) 
or CD9−/− and WT donor mice (expressing CD45.2 leukocyte 
antigen) by flushing with PBS. Erythrocytes were lysed (ACK lysis 
buffer, Lonza) for 1 min on ice. After a washing step, cells were 
resuspended in PBS at 1 × 108/ml. This cell suspension (100 µl) was 
injected intravenously into 13 Gy-irradiated recipient mice 48 h 
postirradiation. Four chimera groups were generated: WT > WT 
(WT cells expressing CD45.1 into WT mice expressing CD45.2); 
WT >  CD9−/− (WT  cells expressing CD45.1 into CD9−/− mice 
expressing CD45.2); WT >  WT (WT  cells expressing CD45.2 
into WT mice expressing CD45.1); CD9−/− > WT (CD9−/− cells 
expressing CD45.2 into WT mice expressing CD45.1). Bone 
marrow reconstitution was verified after 8  weeks by staining 
for CD45.1 or CD45.2 in blood cells with anti-CD45.1 or anti-
CD45.2 specific antibodies (BD Biosciences).
FigUre 1 | Continued
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FigUre 1 | CD9-deficiency reduces sensitivity to dextran sodium sulfate (DSS)-induced colitis. (a) Top, body-weight loss in WT and CD9−/− mice after 
administration of 2% DSS in drinking water for 7 days. Controls for each genotype were administered with unadulterated drinking water. Bottom, disease activity 
index (DAI) score in WT and CD9−/− mice after administration of 2% DSS for 7 days. n = 10–12 per group; *P < 0.05; **P < 0.005; ***P < 0.001, unpaired t-test.  
(B) Macroscopic colon damage in DSS-treated WT and CD9−/− mice. Top, Colon shrinkage. Bottom, changes in colon length. Representative colons are shown of 
n = 10–12 mice per group. (c) Representative photomicrographs of proximal colon (near the cecum) and distal colon (near the anus) from WT and CD9−/− mice at 
day 7 of DSS administration (H&E; magnifications: 4× and 10×). (D) Histological scores obtained from H&E-stained proximal and distal colon tissue sections from 
DSS-treated WT and CD9−/− mice. Data are pooled from two independent experiments (n = 4). Values represent mean ± SD of the mean: *P < 0.05; **P < 0.005; 
***P < 0.001, unpaired t-test.
FigUre 2 | Continued
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FigUre 2 | Enhanced epithelial barrier integrity and survival in CD9−/− mice after dextran sodium sulfate (DSS) challenge (a) In vivo colon permeability, indexed from 
the serum level of 4 kDa FITC-dextran 4 h after feeding by gavage. Data are pooled from two independent experiments, n = 5–6 animals per group. Data were 
analyzed by one-way ANOVA and the Newman–Keuls multiple comparison test; ***P < 0.001. (B) qPCR analysis of tight junction and mucin gene expression in 
colon samples after 7 days of DSS exposure. Data are from one experiment repeated two times with similar results. (c) Kaplan–Meier survival for WT and 
CD9−/− mice given 4% DSS in drinking water. **P < 0.01, Log-rank (Mantel–Cox) test. (D) Percentage of initial body weight of WT and CD9−/− mice after 7-day intake 
of 4% DSS chased by unadulterated water. n = 11–12 per group: *P < 0.05; **P < 0.005; ***P < 0.001; unpaired t-test for WT and CD9−/− groups in (B,c).
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In Vivo Permeability assay
Food was withdrawn overnight and mice were gavaged with the 
permeability tracer FITC-dextran (MW 4,000; Sigma-Aldrich) 
at 60 mg/100 g body weight. After 4 h, blood was collected by 
heart puncture and serum FITC-dextran was measured with a 
fluorescence spectrophotometer (Fluoroskan Ascent; Thermo 
Labsystems) using emission and excitation wavelengths of 490 
and 520  nm, respectively. FITC-dextran concentration was 
determined from a standard curve generated by serialdilution.
isolation and Flow cytometry analysis  
of colonic leukocytes
Colons were dissected longitudinally, washed several times 
with PBS to remove feces, and cut into small pieces. Samples 
were digested with 0.25 mg/ml Liberase TM (Roche), 50 µg/ml 
DNAseI (Roche), and 1  mM DTT diluted in Hank’s Balanced 
Solution for 30 min at 37°C. At the end of the incubation period, 
enzyme activity was blocked by adding 50 ml PBS supplemented 
with 0.5% BSA and 0.05 mM EDTA (PBS–BSA–EDTA), and the 
sample was mechanically disrupted by passing through a 70-μm 
cell strainer to obtain a cell suspension. When only epithelial cells 
were required, samples were incubated in 5 mM EDTA, 1 mM 
DTT for 20 min before enzyme digestion. Before all staining pro-
cedures, colon cell suspensions were incubated with anti-mouse 
FcRII/III (clone 2.4G2, TONBO Biosciences) for 10 min at 4°C 
in PBS-BSA-EDTA. Flow cytometry analysis of DSS-induced 
inflammation was performed with anti-mouse antibodies to the 
following antigens: CD45 (BD Horizon) and CD11b, CD64, and 
Ly6G (BD Pharmingen). For epithelial cell proliferation analysis, 
antibodies were used targeting EpCAM (Biolegend) and Ki67 
(BD Pharmingen). Absolute cell numbers were obtained using 
TruCount Tubes (BD Biosciences). Cell samples were acquired 
in a FACSCanto Flow Cytometer (BD Biosciences), and the 
data were analyzed with FlowJo (Tree Star) or FACSDiva (BD 
Biosciences) software.
Flow cytometric Bead array (cBa)
Serum TNF-α, IL-6, and IFNγ were determined using the mouse 
Th1/Th2/Th17 BD CBA.
rna extraction and real-time  
Quantitative Pcr
RNA was isolated by disrupting colon tissue samples with TRIzol 
Reagent (1 ml per 50–100 mg tissue, Qiagen) and homogenizing 
in a tissue disruptor (Ika ultra-turrax T10 homogenizer). DSS 
traces were removed by the LiCl method (Ambion). Residual 
DNA contamination was eliminated with the Turbo DNA-free 
Kit (Ambion). Total RNA (1  µg) was reverse transcribed to 
cDNA with a Reverse Trancription Kit (Applied Biosystems). 
Quantitative PCR was then performed in an AB7900_384 
(Applied Biosystems) using SYBR Green (Applied Biosystems) 
as the reporter. Gene-specific primers used are listed in Table 
S1 in Supplementary Material. Expression of each gene of 
interest was normalized to housekeeping gene GAPDH. Data 
are presented as relative fold differences calculated by the 2−ΔΔCt 
method.
In Vitro T cell Differentiation
Naive CD4+ T  cells were obtained by incubating single-cell 
suspensions of spleen and lymph nodes with biotinylated 
antibodies to CD8, CD16, CD19, F4/80, Gr-1, MHC class II 
(I-Ab), CD11b, CD11c, and DX5 followed by incubation with 
Streptavidin Microbeads (MACS, Miltenyi Biotec). CD4+ 
T cells were isolated by negative selection in an auto-MACSTM 
Pro Separator (Miltenyi Biotec). Next, cells were activated with 
plate-bound anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) in 
RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% 
FCS, 2 × 10−3 M l-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 50 µM 2-mercaptoethanol, and the correspond-
ing cytokine cocktail: for Th0, anti-IFNγ (4 µg/ml), anti-IL-4 
(4  µg/ml), and IL-2 (10  ng/ml); for Th1 anti-IL-4 (4  µg/ml), 
IL-12 (10 ng/ml), and IL-2 (10 ng/ml); for Th17 anti-IFNγ (4 µg/
ml), anti-IL-4 (4 µg/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), and 
TGF-β1 (5 ng/ml); and for Treg anti-IFNγ (4 µg/ml), anti-IL-4 
(4 µg/ml), and TGF-β1 (10 ng/ml). After 72 h of culture, IFNγ, 
IL-17, or IL-10 in the supernatant were measured by ELISA 
(Ready-SET-Go, eBiosciences). For FACS analysis, intracellular 
cytokine staining was preceded by restimulation for 4 h with 
50 ng/ml phorbol dibutyrate (PMA) and 500 ng/ml ionomycin 
in the presence of brefeldin A (1 µg/ml) (BD Biosciences).
immunofluorescence and 
immunohistochemical analysis
For IF and IHC staining, colon sections were deparaffinized, 
boiled in antigen retrieval solution (10  mM Tris Base, 1  mM 
EDTA Solution, 0.05% Tween 20, pH 9.0 for Ki67 and 10  mM 
sodium citrate, 0.05% Tween 20, pH  =  6 for caspase-3), and 
incubated with the rabbit monoclonal anti-mouse Ki67 primary 
antibody (Master Diagnostica, clon SP6) for IF or anti active 
caspase-3 rabbit polyclonal antibody for IHC (R&D system, 
catalog AF835). Bound antibodies were detected with a goat 
anti-rabbit 647 (ThermoFischer Scientific) for IF or the anti-
rabbit EnVision FLEX-HRP detection system (Agilent) for IHC. 
Staining was developed with DAB substrate (Dako K3468), and 
slides were counterstained with Mayers Hematoxylin. Ki67 and 
FigUre 3 | Continued
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FigUre 3 | CD9−/− mice exhibit lower leukocyte infiltration and proinflammatory cytokines in serum and colon after 2% dextran sodium sulfate (DSS) administration. 
(a) Flow cytometry analysis of whole colon from WT and CD9−/− mice after 7-day 2% DSS intake. Representative dot plots and percentage quantification of CD45+ 
populations show similar DSS-induced infiltration by neutrophils (Ly6G+) and macrophages (CD64+) in both genotypes. (B) Total neutrophil and macrophage 
numbers in the CD45+-gated population, determined by TruCount Tubes. Data are pooled from two independent experiments. For (a,B), n = 6–7 mice per group 
with two repeats and analysis by one-way ANOVA and the Newman–Keuls multiple comparison test. *P < 0.05; **P < 0.005; ***P < 0.001. (c) Serum levels of 
TNF-α, IL-6, and IFNγ measured by cytometric bead array assay. (D) qPCR analysis of colonic proinflammatory cytokine mRNA expression. Bars denote the 
mean ± SD of n = 4–5 mice per genotype. Data from (c,D) were analyzed by two-way ANOVA and the Bonferroni multiple comparison test.
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active caspase-3 staining in epithelial cells were quantified in the 
whole colon sections from each DSS-treated mouse (4–5 mice 
per group). Image J (1.46r) was used to measure Ki67 positive 
individual nuclei and to measure caspase-3 intensity relative to 
the total area corresponding to the complete epithelial layer in 
each image.
statistical analysis
Data are presented as mean  ±  SD. Normal data distribution 
was assessed with the Kolmogorov Smirnov test, and the sta-
tistical significance of between-group differences was assessed 
by one-tailed unpaired Student’s t-test or one-way ANOVA 
with Newman–Keuls multiple comparison t-test, as required. 
All statistical analyses were performed with GraphPad Prism 
(GraphPad Software Inc.).
resUlTs
cD9−/− Mice are Protected against  
Dss-induced colonic injury
To explore the function of CD9 in colitis development, we chal-
lenged CD9−/− and WT mice with the toxic compound DSS (2% 
solution) in drinking water for 7 days. CD9−/− animals lost less 
than 10% of their initial body weight, whereas WT counterparts 
lost around 20% (Figure 1A, top). To monitor disease activity, we 
recorded a daily disease activity index (DAI) combining weight 
loss, stool consistency, and bleeding. From day 4, DAI values 
were lower in CD9−/− mice than in WT counterparts (Figure 1A, 
bottom). Autopsy revealed that DSS-treated CD9−/− mice had 
significantly larger colons than WT counterparts (Figure  1B). 
Histology revealed a better preservation of tissue architecture 
in CD9−/− mice, in both the proximal and the distal colon. DSS-
treated WT animals showed more pronounced epithelial denuda-
tion, crypt distortion, leukocyte infiltration of the lamina propria, 
and submucosal swelling (Figure 1C). Histological sections were 
scored for the severity of DSS-induced inflammation as described 
in Section “Materials and Methods.” In both proximal and distal 
colon, histological scores were lower in CD9−/− mice than in WT 
mice, with the difference more pronounced in the distal colon 
(Figure 1D).
cD9 exacerbates Tissue injury  
and Decreases Mouse survival  
after a lethal Dss Dose
Intestinal epithelial integrity is necessary for efficient defense 
against intraluminal toxins, antigens, and enteric bacteria. Cells 
are tightly joined in a healthy epithelium, and transepithelial 
permeability can thus be determined as an index of epithelial 
integrity. To monitor gut barrier function in vivo, we treated 
CD9−/− and WT animals with 2% DSS for 7 days and then orally 
administered 4KDa FITC-Dextran. Fluorescence spectropho-
tometry detection of serum FITC after 4 h revealed markedly 
lower gastrointestinal permeability in CD9−/− mice than in WT 
mice (Figure 2A). Serum FITC levels in non-treated animals 
showed no significant between-genotype differences and 
remained below 5 μg/ml, consistent with an intact intestinal 
barrier function in the steady state (Figure  2A). Consistent 
with the FITC-Dextran data, qPCR of colon samples from 
DSS-treated CD9−/− mice revealed elevated expression of 
genes encoding epithelial tight junction proteins, such as 
ZO-1, tricellulin, and claudin family members (Figure  2B). 
CD9−/− colon also showed elevated expression of genes encod-
ing epithelial globet cell proteins, such as the secretory mucin 
glycoproteins MUC1, MUC2, and trefoil factor 3, indicating 
normal intestinal function (Figure 2B). In a further approach, 
we exposed mice to a lethal DSS dose (4%) for 7 days followed 
by unadulterated drinking water for a further 8  days. At the 
end of the experiment all WT mice had died, whereas only 
45% of the CD9−/− group were dead (Figure  2C). Moreover, 
the surviving CD9−/− mice showed a recovery in body weight 
(Figure 2D). These results show that CD9 impedes epithelial 
repair and contributes to colon injury at both sublethal and 
lethal DSS doses.
reduced Myeloid cell infiltration and 
Proinflammatory cytokine expression  
in the colon of cD9−/− Mice
To characterize the immune mechanisms of colonic mucosa dam-
age, we analyzed CD9−/− and WT colon cells by flow cytometry. 
After 7-day exposure to 2% DSS, CD9−/− colon showed markedly 
lower neutrophil and macrophage infiltration than WT colon 
(Figures 3A,B). In contrast, in non-treated mice, gut populations 
of these immune cell subsets were comparable between genotypes 
(Figures 3A,B), as were mesenteric lymph nodes, intraepithelial 
lymphocyte and lamina propria populations (Figure S1 in 
Supplementary Material). DSS-treated CD9−/− mice also had 
lower serum levels of IL-6 and TNFα than WT mice, whereas 
IFNγ was similarly increased in response to DSS in both geno-
types (Figure 3C). Analysis of colon samples by qPCR revealed 
lower DSS-induced levels of IL-6, IL-1β, NLPR3, iNOS, IL-12p35, 
and IL-12p40 mRNA in CD9−/−animals, whereas IL-17, IL-22, 
and IFNγ showed no significant between-genotype differences 
(Figure 3D).
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FigUre 4 | Continued
FigUre 4 | CD4+ T cell-expressed CD9 does not contribute to adoptive transfer-mediated colitis or T cell differential subset skewing. (a) Top, body weight 
after intraperitoneal adoptive transfer of CD4+CD45RBhi CD62L+CD25− T cells from WT and CD9−/− donors into Rag1−/− recipients. Bottom, colon length at 
sacrifice on day 57. Data are from a representative experiment repeated three times with similar results. n = 5–6 mice per group; unpaired t-test. ns, non 
significant. (B) Representative 3.5× and 10× magnification H&E-stained colonic sections from Rag1−/− mice injected with WT and CD9−/− CD4+ cells, 
showing transmural infiltration affecting all colon layers in both settings. (c) FACS analysis of myeloid cell infiltration. Representative dot plots are shown on 
the left; quantification of CD45+-gated cell percentages and total numbers is shown on the right. (D) Flow cytometry analysis of intracellular staining for 
IFNγ and IL-17 in T cells from the mesenteric lymph nodes (MLNs) of RAG1−/− mice 2 months after CD4+ T cell transfer. Cells were cultured for 72 h on an 
anti-CD3/CD28-coated plate and brefeldin A was added for the last 4 h. Representative dot plots and bar quantifications are shown of CD4+CD25+-gated 
cells. n = 5–6 mice per group; unpaired t-test. (e) In vitro T cell differentiation toward Th1, Th17, and Treg CD4+ T cell subsets. Representative dots plots 
are shown of intracellular IFNγ, IL-17, and IL-10 in sorted populations, with quantification on the right (top row). Cytokine release was quantified by ELISA 
(bottom). Data are from a representative independent experiment of three performed and are presented as mean ± SD. n = 5 per genotype; unpaired 
t-test.
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cD9 expressed on cD4+ T cells Does  
not contribute to immune-cell adoptive 
Transfer-Mediated colitis
To further explore possible CD9-mediated immune mecha-
nisms in IBD, we used an alternative model of colitis induced 
by intraperitoneal transfer into Rag1−/− mice of CD4+CD62L+ 
CD25−CD45RBhi naive T cells sorted from WT or CD9−/− mice. 
Body weight was recorded over 2 months, showing no between-
group differences (Figure 4A, top). Colon shortening was also 
similar in both genotypes (Figure 4A, bottom). Consistent with 
these findings, histological analysis revealed a similar extent 
of transmural inflammation in injected animals (Figure 4B), 
and flow cytometry showed similar increases in neutrophil 
and macrophage infiltration (Figure  4C). Restimulation of 
mesenteric lymph node CD4+ cells with CD3/CD28 revealed 
no significant differences in Th1 and Th17 effector cell 
populations or cytokine production (Figure 4D). Likewise, no 
between-genotype differences were observed in the percent-
ages of Th1, Th17, and Treg cells upon in vitro polyclonal dif-
ferentiation of CD4+ naive T cells from CD9−/− and WT mice 
(Figure 4E).
cD9−/− Bone Marrow cells Transplanted 
into WT Mice Do not Provide Protection 
against colonic injury
We next investigated the possible role of CD9 in myeloid cell 
populations or the resident non-hematopoietic cell compartment 
(mainly endothelial and epithelial cells). Two groups of chimeric 
mice were generated using the CD45.1 and CD45.2 haplotypes. 
Flow cytometry showed reconstitution levels of 95–99% (data not 
shown). Reconstitution experiments were carried out with WT 
CD45.1 mice and CD9−/− or WT CD45.2 mice, with irradiation 
and transplantation in either direction. Protection against DSS-
induced colitis was observed only when irradiated CD9−/− mice 
were used as recipients of WT bone marrow (Figures  5A,B). 
Histology revealed typical DSS-induced changes in the distal and 
proximal colon of WT recipients and less pronounced alterations 
in CD9−/− recipients reconstituted with CD45.1 WT bone marrow 
(Figures 5C,D). Only CD9−/− recipients had lower DSS-induced 
levels of serum IL-6 measured by ELISA (Figure  5E), and 
colon samples from CD9−/− recipients also had lower induced 
transcript expression of proinflammatory cytokines measured 
by qPCR (Figure 5F). These results underscore the conclusion 
that susceptibility to DSS-induced colitis is increased by CD9 
expression in the non-hematopoietic compartment.
enhanced colonocyte Proliferation after 
Dss-induced injury in cD9−/− Mice
After DSS-induced epithelial cell damage, the colonic epithelium 
actively proliferates to restore intestinal barrier integrity. Flow 
cytometry analysis of the proliferation marker Ki67 in colonic 
EpCAM+ intestinal epithelial cells (IECs) from mice revealed 
that CD9 deficiency supports elevated colonic epithelial cell 
proliferation after DSS exposure (Figure 6A, top). However, no 
differences were detected in the proliferation of epithelial cells 
extracted from non-treated animals (Figure S2 in Supplementary 
Material). Remarkably, although the percentage of Ki67+ cells 
was slightly higher in CD9−/− colon after 2 and 4  days of DSS 
exposure, the significant difference was observed at day 6. This 
is coincident with significant lower body weight loss and higher 
colon length in CD9−/− mice (Figure  6A, bottom). Moreover, 
CD9−/− colon showed higher mRNA expression of c-myc, c-fos, 
and cyclin D1 (Figure 6B). Analysis of the apoptosis marker cas-
pase-3 was carried out by IHC in DSS-treated chimeric mice, with 
no differences between genotypes (Figure S3 in Supplementary 
Material). Proliferation in DSS-exposed colon of these animals 
was determined by counting immunostained Ki67+ cells in colon 
crypts on histological sections. The percentage of Ki67+ colonic 
cells was higher after DSS exposure in CD9−/− recipients than 
in WT recipients (Figures 6C,D). Taken together, these results 
demonstrate that CD9 limits epithelial cell proliferation in 
response to injury.
DiscUssiOn
Inflammatory bowel disease arises through close interaction 
between genetics, immunology, environment, and microbi-
ome. The development and progression of this multifactorial 
disorder is affected by several factors, including diet, lifestyle, 
and behavior. Moreover, perturbations of the gut microbiota 
due to antibiotic medication may also play an important role 
in IBD. DSS-induced colitis has become a widely used model 
for studying IBD in the mouse (25, 26). DSS is a chemical 
colitogen toxic to gut epithelial cells, interfering with intesti-
nal barrier function and stimulating local inflammation. This 
FigUre 5 | Continued
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FigUre 5 | Lack of CD9 in the resident non-hematopoietic compartment confers the reduced susceptibility to dextran sodium sulfate (DSS)-mediated colitis. 
Lethally irradiated WT CD45.1 mice were rescued with WT or CD9−/− CD45.2 bone marrow, whereas lethally irradiated WT and CD9−/− CD45.2 mice were rescued 
with WT CD45.1 bone marrow. Three months post-transplantation mice were treated with 2% DSS. (a) Body weight evolution. (B) Disease activity index and  
colon shortening. (c) H&E stained proximal and distal colon sections. (D) Histological injury scores. (e) Serum IL-6 measured by ELISA. (F) qPCR analysis of 
proinflammatory cytokine expression in the colon of WT or CD9−/− CD45.2 recipients. Experiments were perfomed twice, giving similar results. n = 6–7 per group.  
All between-group comparisons were analyzed by unpaired t-test; *P < 0.05; **P < 0.005; ***P < 0.001.
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model is suitable for studying events triggered by temporary 
failure of mucosal homeostasis after epithelial cell shedding 
and loss of barrier integrity, and can also provide insight into 
the mechanisms that lead to MH after initial injury (27). Here, 
we report protection against DSS-induced colonic mucosal 
damage in CD9-deficient mice. These mice show lower DAI 
scores throughout treatment, larger colons, and have a less 
severe histological injury. The protection conferred by CD9 
absence was confirmed by the increased survival of CD9−/− 
mice upon administration of a lethal 4% DSS dose. Epithelial 
preservation in  vivo was demonstrated by lower colonic 
transepithelial FITC-dextran leakage in CD9−/− mice, and the 
importance of CD9 in the control of intestinal epithelial barrier 
function and integrity was further demonstrated by preserved 
expression of tight junction and other barrier-related genes in 
CD9−/− mice.
CD9 is ubiquitously expressed, and we therefore performed 
chimeric reconstitution experiments to determine which 
cell compartment is responsible for mediating DSS-induced 
toxicity. Our data clearly demonstrated that protection in 
CD9−/− animals was not dependent on the hematopoietic cell 
compartment. In CD9−/− colon, crypt and villous distortion is 
minimal and surface epithelium is more preserved; this keeps 
luminal pathogens outside the lamina propria, and therefore 
proinflammatory cytokine and chemokine release is lower 
and there is less inflammatory cell recruitment. Specifically, 
the myeloid-derived cytokines involved in the inflammatory 
response in DSS acute colitis iNOs, TNF-α, IL-6, IL-12, and 
the inflammasome drivers NLRP3 and IL-1β were enhanced in 
WT mice versus CD9−/− mice, but no differences were observed 
in either IFNγ, IL-17, or IL-22 cytokines. DSS colitis can be 
exacerbated by granulocyte recruitment (28–30). However, the 
reconstitution experiments ruled out a contribution to colon 
protection from CD9 deficiency in innate immune cells. The 
role of endothelial CD9 could not be completely discarded, and 
additional research with endothelium-specific deletion of CD9 
would be required to resolve this issue. In addition, CD9 plays an 
important role in T cell activation (31–34). However, our data in 
the adoptive T cell transfer-mediated colitis model and in vitro 
T cell polyclonal experiments showed no significant differences 
in the differentiation and activation of CD9-deficient and WT 
Th1 and Th17 T cell subsets.
Flow cytometry and immunohistochemistry analysis 
revealed a higher percentage of Ki67 IECs in DSS-exposed 
CD9−/− colon. In the distal colon, the percentage Ki67+ cells 
is lower than in the proximal colon. This likely reflects the 
more severe colitis in the middle and distal third of the colon 
in DSS-exposed mice, causing a predominantly distal injury 
characterized by epithelial ulceration and impaired regenera-
tion (35). Notably, the difference in proliferation was observed 
after 6  days of DSS exposure, suggesting that it is related to 
mechanisms of post-injury epithelial recovery. CD9 absence 
thus does not increase IEC proliferation per se and only sup-
ports MH after injury. Indeed, hyperplasia and dysplasia were 
not observed in any CD9−/− animals after cessation of DSS 
exposure.
Dextran sodium sulfate treatment leads to the exposure of the 
Toll-like receptors on the IEC basolateral surface. This triggers a 
proliferation that contributes to mucosal repair after injury, and 
DSS-induced colitis is exacerbated in mice with gene deletions 
affecting TLR signaling such as Tlr2−/−, Tlr4−/−, and Myd88−/− 
(36–38). TLR signaling is linked to EGFR activation (39), which 
is required for intestinal homeostasis in the setting of acute 
mucosal damage (40, 41). CD9 could be playing several roles in 
these settings. EGFR signaling is increased in CD9-deficient cell 
lines (17, 42), and CD9 also negatively regulates ADAM17 (16) 
metalloproteinase activity, which is known to shed some EGFR 
ligands. CD9 deficiency will thus translate into increased EGFR 
phosphorylation and activation. Aside from a direct control of pro-
liferation, CD9 might regulate epithelial restitution, its deficiency 
ultimately resulting in increased epithelial proliferation (43). 
In this context, CD9 absence might facilitate rapid resealing of 
the intestinal epithelial barrier and could promote IEC migra-
tion through impaired localization of talin-1 to focal adhesions 
(10) or increase CXCR4/CXCL12-mediated migration (44), a 
route that directly regulates epithelial cell migration, barrier 
maturation, and restitution (45). Compared with CD9-positive 
cells, CD9-negative or depleted epithelial and tumor cells have 
a much higher migratory capacity, thereby supporting epithelial 
restitution (42, 46).
Inflammatory bowel disease is effectively treated with 
anti-TNF-α monoclonal antibody (Infliximab), either as 
monotherapy or in combination with other immunomodula-
tors, and current efforts are directed toward the crucial goal 
of achieving MH in order to accomplish long-term remission 
(4, 47). However, pharmacological anti-inflammatory agents 
such as glucocorticosteroids or 5-aminosalicylic acid do not 
heal the bowel mucosa (4), and the efficacy of growth factors 
such as GH and EGF has yet to be established (48). There is 
thus a clear need to identify new therapeutic targets for MH. 
Our results indicate that CD9 depletion enhances IEC prolif-
eration, resulting in a high regenerative response and reduced 
susceptibility to DSS-induced colitis. Our findings thus reveal 
a critical role for the tetraspanin CD9 in colon inflammation 
and suggest a novel therapeutic opportunity. Growing recent 
evidence suggests that targeting tetraspanins by an array of 
FigUre 6 | Continued
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FigUre 6 | CD9 limits epithelial cell proliferation upon dextran sodium sulfate (DSS) challenge. (a) Top, FACS analysis of Ki67+ cells in the EpCAM+CD45− gated 
population after days 2, 4, and 6 days 2% DSS exposure (upper panel). Bottom, body weight loss and colon shortening, n = 5–6 mice per group. (B) qPCR analysis 
of colonic mRNA expression of the cell-cycle genes c-myb, ccdn1, and c-fos. Data are pooled from two independent experiments, n = 4–6 mice per group. (c) 
Ki67 immunofluorescence staining on proximal and distal colon sections from untreated or 6-day DSS-treated chimeric mice. Representative magnification images 
are shown. (D) Quantification of Ki67+ cells in the epithelial layer of proximal (upper), and distal (lower) colons from 6-day DSS-fed chimeric mice. Each dot 
corresponds to the percentage of Ki67+ nuclei from all the epithelial nuclei of whole colon sections n = 4–5 mice per genotype. Between-group comparisons were 
analyzed by unpaired t-test for (a,B) and Mann–Whitney U-test for (D); *P < 0.05; **P < 0.005; ***P < 0.001.
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tools including monoclonal antibodies, soluble large-loop 
proteins, and RNAi technology may be used to improve 
the course of IBDs.
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